IL10 and gastric cancer: The level of CXCL13 was also increased in gastric cancer patients (Figure 2(h), 44.52 (16.89, 63.26) vs. 8.62 (0.22, 48.25), pg/ml, P = 0.017), while there was no difference in the IL-21 and IL-10 levels (Figure 2(g), 171.31 (109.13, 268.31) vs. 200.47 (91.71, 314.74), pg/ml, P = 0.515; Figure 2(i), 2.28(2.01, 2.76) vs. 2.09(1.80, 3.08), pg/ml, P = 0.295).